5-Amino-1MQ

A small molecule that blocks the enzyme NNMT, sold widely as a metabolic capsule despite having no published human trials.

What it is

5-Amino-1MQ is not a peptide, despite usually being sold beside them. It is a small molecule that inhibits nicotinamide N-methyltransferase, or NNMT, an enzyme that chemically tags nicotinamide and sends it toward disposal.

Nicotinamide is a precursor for NAD+, the coenzyme that sits at the center of energy metabolism. The theory is that blocking NNMT leaves more nicotinamide available for NAD+ production inside fat and muscle tissue, where NNMT activity rises with obesity.

What the evidence actually covers

In diet-induced obese mice, small molecule NNMT inhibitors reduced fat mass and body weight without reducing food intake. Those results were real and reproducible enough to attract drug development interest.

There are no published randomized trials of 5-Amino-1MQ in humans. No dose has been established, no safety profile exists in people, and there is no evidence about what happens when NNMT is inhibited for months or years in an adult who is not obese. NNMT is also involved in methyl group handling more broadly, which is not a system with an obvious safety margin.

How to read the marketing

Product pages tend to compress mouse fat loss into a human promise. The honest version is that this is a pharmacologically interesting target with a mouse dataset and a marketing department.

If the goal is fat loss with evidence behind it, the medications with large randomized outcome trials are the incretin agonists, not this.

Baseline does not dispense this. It is here because people ask about it, and because an honest read of the evidence is more useful than a sales page.

References

  1. Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochem Pharmacol. 2018.
  2. Kannt A, et al. A small molecule inhibitor of nicotinamide N-methyltransferase for the treatment of metabolic disorders. Sci Rep. 2018.